KRAS and leukemia: The aim of the current study is to set a comparative study between loaded nanomedicine as titanium nanoformulation-loaded cisplatin and titanium nanoformulation-loaded doxorubicin with their non-loaded analogs (cisplatin and doxorubicin) and between lactoferrin-loaded doxorubicin and lactoferrin loaded-cisplatin with their non-loaded analogs and neupogen (standard drug) against DMBA-induced leukemia via monitoring the crosstalk between Hprt/K-RAS/c-myc/SAT-2/P53/JAK-2-signaling pathways.